An Open-Label Ascending Single-Dose, and Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CST-2032 in Healthy Volunteers and Subjects with Mild Cognitive Impairment or Parkinson's Disease

  • O'Brien, Terence (Primary Chief Investigator (PCI))
  • Kerris, Jarrod (Project Manager)

Project: Research

Project Details

Effective start/end date29/07/2131/12/24


  • Mild cognitive impairment
  • Parkinson's disease
  • Clinical trial